Chinese Expert Consensus on the Standardized Diagnosis and Treatment of Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations(2024 Edition)
10.3779/j.issn.1009-3419.2024.102.27
- VernacularTitle:EGFR 20外显子插入突变非小细胞肺癌规范化诊疗中国专家共识(2024版)
- Author:
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
;
ZHOU CAICUN
- Keywords:
Lung neoplasms;
EGFR ex20ins mutations;
Standardized diagnosis and treatment;
Consensus
- From:
Chinese Journal of Lung Cancer
2024;27(7):485-494
- CountryChina
- Language:Chinese
-
Abstract:
The standard clinical practice of managing the non-small cell lung cancer(NSCLC)with epider-mal growth factor receptor(EGFR)exon 20 insertion(ex20ins)mutations was elaborated in Chinese expert consensus on non-small cell lung cancer with EGFR exon 20 insertion mutations(2023 edition),and this rare subset has gradually attracted attention recently.With the deepening of treatment area exploration and the approval of new targeted drugs,there are more options for the diagnosis and treatment of EGFR ex20ins positive NSCLC patients.Therefore,based on the previous version of consensus,the expert panel has updated this consensus on the standardized clinical diagnosis and treatment of EGFR ex20ins mutation NSCLC through reference to literature and clinical data,and combined with the experts'own clinical experience.The updated recommendations includes disease congnition,testing methods,therapy and recent relevant clinical trials for NSCLC patients with EGFR ex20ins mutation,in order to provide better medication reference for clinical physicians.
